Your session is about to expire
← Back to Search
CorNeat EverPatch for Glaucoma
Study Summary
This trial is designed to demonstrate the safety of the CorNeat EverPatch for concealment of artificial implants and glaucoma tube shunts. The study will enroll 10 subjects who will be monitored for a period of 12 months.
- Glaucoma
- Tissue Necrosis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Who would be the most ideal participants for this research endeavor?
"This clinical trial is now attempting to recruit 10 people with glaucoma who are between the ages of 18 and 80. Additional eligibility requirements include being male or female, possessing functional tear film and lids, having visual acuity of light perception or better, as well as using an effective contraceptive throughout the duration of their participation in the study. Furthermore, participants must be willing to attend all scheduled visits and comply with all procedures set forth by this research team."
Are there any restrictions on this clinical investigation based upon age?
"In accordance with the conditions set forth, this clinical trial seeks participants aged 18-80."
Are there still patient slots available for this experiment?
"Clinicaltrials.gov reveals that this clinical trial, which was made available on December 11th 2020 and most recently updated on April 17th 2022, is no longer actively seeking participants. Nevertheless, there are 206 other studies presently enrolling patients."
Share this study with friends
Copy Link
Messenger